SBRT is a recognised treatment for low and intermediate risk prostate cancer with 36.25Gy in 5 fractions the most commonly used regimen. We explored the preliminary efficacy, patient recorded toxicity and decision regret in intermediate and high risk prostate cancer receiving SBRT with PSMA/MRI guided focal gross tumor volume (GTV) boost to 45Gy.